Attached files

file filename
EX-32 - EXHIBIT 32.1 CERTIFICATION - OPT SCIENCES CORPexhibit_32-1_1q_2015.htm
EX-31 - EXHIBIT 31.1 CERTIFICATION - OPT SCIENCES CORPexhibit_31-1_1q_2015.htm
EXCEL - IDEA: XBRL DOCUMENT - OPT SCIENCES CORPFinancial_Report.xls

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-Q

(Mark One)
þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended January 31, 2015.
or
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______________ to ______________.
   
   

Commission File Number: 0-1455

OPT-SCIENCES CORPORATION

(Exact name of registrant as specified in its charter)


NEW JERSEY 21-0681502
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)

1912 BANNARD STREET, CINNAMINSON, NEW JERSEY 08077
(Address of principal executive offices) (Zip Code)

(856) 829-2800

(Registrant's telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES þ NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES þ NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o Accelerated filer o
Non-accelerated filer o Smaller reporting company þ
(Do not check if smaller reporting company)    

Indicate by check mark whether the registrant is a shell company(as defined in Rule 12b-2 of the Exchange Act). YES o NO þ


Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practical date: 775,585 Shares of Common Stock, par value $0.25, were outstanding as of March 12, 2015.



Opt-Sciences Corporation
FORM 10-Q FIRST QUARTER REPORT - FISCAL YEAR 2015

TABLE OF CONTENTS

    Page
PART I FINANCIAL INFORMATION  
     
Item 1. Financial Statements. 3
     
  Consolidated Balance Sheets as of January 31, 2015 (unaudited) and November 1, 2014. 3
     
  Consolidated Statements of Income and Comprehensive Income (unaudited) for three months ended January 31, 2015 and three months ended January 25, 2014. 5
     
  Consolidated Statements of Retained Earnings (unaudited) for three months ended January 31, 2015 and three months ended January 25, 2014. 5
     
  Consolidated Statements of Cash Flows (unaudited) for three months ended January 31, 2015 and three months ended January 25, 2014. 6
     
  Notes to Consolidated Financial Statements. 7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. 9
Item 3 Quantitative and Qualitative Disclosures About Market Risk. 10
Item 4. Controls and Procedures. 10
PART II OTHER INFORMATION 11
Item 1. Legal Proceedings. 11
Item 1A. Risk Factors. 11
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 11
Item 3. Defaults Upon Senior Securities. 11
Item 4. Mine Safety Disclosures. 11
Item 5. Other Information. 11
Item 6. Exhibits. 11
  Signatures. 11

2



PART I   FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

Opt-Sciences Corporation

CONSOLIDATED BALANCE SHEETS

ASSETS

    January 31, 2015
(Unaudited)
  November 1, 2014
CURRENT ASSETS                
                 
Cash and cash equivalents   $ 3,716,297     $ 3,259,372  
Marketable securities     8,076,372       8,001,647  
Trade accounts receivable     1,410,385       1,495,707  
Inventories     765,245       858,253  
Prepaid expenses     12,639       17,069  
Loans and exchanges     5,610       4,820  
Accrued interest receivable     51,629       54,563  
                 
Total current assets     14,038,177       13,691,431  
                 
                 
PROPERTY AND EQUIPMENT                
Land     216,406       216,406  
Building and improvements     985,944       980,398  
Machinery and equipment     2,209,846       2,202,225  
                 
Total property and equipment     3,412,196       3,399,029  
Less accumulated depreciation     2,411,000       2,377,080  
                 
Net property and equipment     1,001,196       1,021,949  
                 
OTHER ASSETS                
Deposits     2,837       2,837  
Total assets   $ 15,042,210     $ 14,716,217  
                 

3



Opt-Sciences Corporation

CONSOLIDATED BALANCE SHEETS

LIABILITIES AND STOCKHOLDERS' EQUITY

    January 31, 2015
(Unaudited)
  November 1, 2014
CURRENT LIABILITIES                
                 
Accounts payable - trade   $ 66,722     $ 92,446  
Accrued income taxes     178,303       20,313  
Accrued salaries and wages     159,250       314,657  
Accrued professional fees     85,071       38,357  
Deferred income taxes     53,979       27,380  
Other current liabilities     23,263       50,408  
                 
Total current liabilities     566,588       543,561  
                 
STOCKHOLDERS' EQUITY                
                 
Common capital stock -par value $0.25 per share -                
authorized and issued 1,000,000 shares     250,000       250,000  
Additional paid in capital     272,695       272,695  
Retained earnings     14,013,758       13,755,871  
Accumulated other comprehensive income:                
Unrealized holding gain on marketable securities     126,387       81,308  
Less treasury stock at cost - 224,415 shares     (187,218)       (187,218)  
Total stockholders' equity     14,475,622       14,172,656  
Total liabilities and stockholders' equity   $ 15,042,210     $ 14,716,217  
                 

4



Opt-Sciences Corporation

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Unaudited)

    Three Months
Ended
January 31, 2015
  Three Months
Ended
January 25,2014
                 
NET SALES   $ 1,796,084     $ 1,330,211  
COST OF SALES     1,153,918       1,044,659  
Gross profit on sales     642,166       285,552  
                 
OPERATING EXPENSES                
Sales & delivery     4,167       914  
General & administrative     306,411       261,648  
Total operating expenses     310,578       262,562  
Operating income     331,588       22,990  
                 
OTHER INCOME     91,099       158,867  
Income before taxes     422,687       181,857  
                 
FEDERAL AND STATE INCOME TAXES     164,800       69,100  
Net income     257,887       112,757  
                 
OTHER COMPREHENSIVE INCOME                
Unrealized holding gains on marketable securities, net of taxes     45,079       (37,596)  
Comprehensive income   $ 302,966     $ 75,161  
                 
EARNINGS PER SHARE OF COMMON STOCK   $ 0.33     $ 0.15  
                 
Average shares of stock outstanding     775,585       775,585  

CONSOLIDATED STATEMENTS OF RETAINED EARNINGS (Unaudited)

    Three Months
Ended
January 31, 2015
  Three Months
Ended
January 25,2014
                 
RETAINED EARNINGS - beginning of period   $ 13,755,871     $ 12,641,792  
Net income     257,887       112,757  
RETAINED EARNINGS - end of period   $ 14,013,758     $ 12,754,549  
                 

5



Opt-Sciences Corporation

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

    Three Months
Ended
January 31, 2015
  Three Months
Ended
January 25,2014
                 
CASH FLOWS FROM OPERATING ACTIVITIES:                
Net income   $ 257,887     $ 112,757    
Adjustments to reconcile net income to net                
cash provided by operating activities:                
Depreciation     33,920       33,820  
Loss (Gain) on sale of securities     17,783       (65,416)  
Decrease (increase) in:                
Accounts receivable     85,322       140,765  
Inventories     93,008       11,631  
Prepaid expenses     4,430       3,098  
Loans and exchanges     (790)       (1,490)  
Accrued interest receivable     2,934       (11,773)  
Deposits     0       19,834  
(Decrease) increase in:                
Accounts payable     (25,724)       (12,654)  
Accrued income taxes     157,990       19,100  
Accrued salaries and wages     (155,407)       (147,322)  
Accrued professional fees     46,714       (23,665)  
Other current liabilities     (27,145)       (26,433)  
Net cash provided by operating activities     490,922       52,252  
                 
CASH FLOWS FROM INVESTING ACTIVITIES:                
Purchases of fixed assets     (13,167)       (69,373)  
Purchases of securities     (521,364)       (376,368)  
Proceeds from sale of securities     500,534       227,375  
Net cash (used) by investing activities     (33,997)       (218,366)  
                 
                 
Increase (decrease) in cash     456,925       (166,114)  
                 
Cash and cash equivalents at beginning of period     3,259,372       3,446,819  
                 
Cash and cash equivalents at end of period   $ 3,716,297     $ 3,280,705  
                 
SUPPLEMENTAL DISCLOSURES:                
Income taxes paid   $ 6,810     $ 50,000  
                 

6



Opt-Sciences Corporation

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying consolidated financial statements include the accounts of Opt-Sciences Corporation, Inc. and its wholly-owned subsidiary, O and S Research, Inc. (collectively, the "Company"). All significant intercompany accounts and transactions have been eliminated in consolidation.

These consolidated financial statements have been prepared by the Company, without audit, and reflect normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the results for the first three months of the Company's fiscal year 2015. These consolidated financial statements do not include all disclosures associated with annual consolidated financial statements and, accordingly, should be read in conjunction with the footnotes contained in the Company's consolidated financial statements for the year ended November 1, 2014 together with the auditors' report filed as part of the Company's 2014 Annual Report on Form 10-K.

The three months that ended January 31, 2015 and the three months that ended January 25, 2014 represent thirteen weeks respectively.

The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

2. INVENTORIES

Inventories consisted of the following:

    January 31, 2015
(Un-audited)
  November 1, 2014
                 
Raw materials and supplies   $ 427,021     $ 441,138  
Work in progress     220,529       285,138  
Finished goods     117,695       131,977  
Total Inventory   $ 765,245     $ 858,253  
                 

End of quarter inventories are stated at the lower of cost (first-in, first-out) or market. The inventory included in the unaudited quarterly financial statements and in this Form 10-Q is based on estimates derived from an unaudited physical inventory count of work-in-progress and raw materials. The Company provides for estimated obsolescence on unmarketable inventory based upon assumptions about future demand and market conditions. If actual demand and market conditions are less favorable than those projected by management, additional inventory write downs may be required. Inventory, once written down, is not subsequently written back up, as these adjustments are considered permanent adjustments to the carrying value of the inventory. The Company conducts an audited physical inventory at the end of the fiscal year in connection with its audited financial statements and preparation of its Form 10-K.

3. REVENUE RECOGNITION

The Company recognizes revenue in accordance with U.S. GAAP and SEC Staff Accounting Bulletin ("SAB") No. 104, Revenue Recognition. SAB No. 104 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the price to the buyer is fixed and determinable; and (4) collectability is reasonably assured. Determinations regarding criteria (3) and (4) are based on management's judgments regarding the fixed nature of the price to the buyer charged for products delivered or services rendered and collectability of the sales price. The Company assesses credit worthiness of customers based upon prior history with the customer and assessment of financial condition. The Company shipping terms are customarily FOB shipping point.

7



4. FINANCIAL INSTRUMENTS

ASC 820, "Fair Value Measurements", requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
   
Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
   
Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company's financial instruments consist principally of cash, cash equivalents, marketable securities, trade accounts receivable, accounts payable and accrued liabilities. Pursuant to ASC 820, the fair value of our cash equivalents and marketable securities is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of all of the other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

5. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

The Company has reviewed all recently issued, but not effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

6. SUBSEQUENT EVENTS

The Company is not aware of any event that occurred subsequent to the balance sheet date but prior to the filing of this report that could have a material impact on our financial position or results of operations.

8



ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
We make statements in this Report, and we may from time to time make other statements, regarding our outlook or expectations for earnings, revenues, expenses and/or other matters regarding or affecting the Company that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements are typically identified by words such as "believe", "expect", "anticipate", "intend", "outlook", "estimate", "forecast", "project" and other similar words and expressions. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made. We do not assume any duty and do not undertake to update our forward-looking statements. Actual results or future events could differ, possibly materially, from those that we anticipated in our forward-looking statements, and future results could differ materially from our historical performance. Our forward-looking statements are subject to the following principal risks and uncertainties:

-   Uncertain demand for the Company's products because of the current international financial concerns;
-   Risks associated with dependence on a few major customers; and
-   The performance, financial strength and reliability of the Company's vendors.

We provide greater detail regarding other factors in our 2014 Form 10-K.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Management's discussion and analysis of financial condition and results of operations are based upon the Company's consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Specifically, inventory is estimated quarterly and reconciled at the end of the fiscal year when an audited physical count is conducted (also see Notes to Consolidated Financial Statements, Note 1 Summary of Significant Accounting Policies and Note 2 Inventories).

EXECUTIVE SUMMARY

Opt-Sciences Corporation, through its wholly owned subsidiary, O and S Research, Inc., both New Jersey corporations, manufactures anti-glare and transparent conductive optical coatings which are deposited on glass used primarily to cover instrument panels in aircraft cockpits. The Company's business is highly dependent on a robust commercial, business, regional and military aircraft market. We recorded first quarter sales of $1,796,084 and net income of $257,887. Sales decreased approximately 27% or $481,275 from the record sales in the fourth quarter of Fiscal Year 2014. Compared to the first quarter of 2014, sales increased approximately 35% or $465,873. We currently expect second quarter sales to be approximately $1,700,000 or slightly lower than the first quarter. International financial concerns and the prospect of higher interest rates may adversely affect aircraft users and purchasers by inhibiting their ability to finance and their desire to purchase new airplanes as well as their ability and desire to upgrade existing aircraft. During the first quarter of 2015, the Company booked $1,973,000 in new orders compared to $1,937,000 in new orders booked for the fourth quarter of 2014 and $1,112,000 in new orders booked in the first quarter of 2014. Our backlog of unshipped orders was approximately $2,132,000 at the end of the first quarter, up approximately $177,000 from the end of the fourth quarter of 2014 and up approximately $237,000 from the first quarter of 2014. The higher backlog is primarily due to the cyclic demands of our customers.

Approximately 95% of the backlog is scheduled for delivery in Fiscal Year 2015. Based on their needs which change from time to time, our customers may accelerate or defer delivery dates; and we typically try to accommodate their needs if we have available manufacturing capacity and access to the required raw materials. We generally have a four to twelve week delivery cycle depending on product complexity, plant capacity and lead time for raw materials, such as polarizers or filter glass. Our sales tend to fluctuate from quarter to quarter, because all orders are custom manufactured and customer orders are generally scheduled for delivery based on our customer's need date and not based on our ability to manufacture and ship our products. Since the Company has two customers and two subcontractors of one of those customers that all together represented approximately 65% of sales for the first quarter, any significant change in the requirements of either of those customers would have a direct impact on our revenue for a quarter or a year.

9



RESULTS OF OPERATIONS - FIRST QUARTER

THREE MONTHS ENDED JANUARY 31, 2015 COMPARED WITH THREE MONTHS ENDED JANUARY 25, 2014

NET SALES
Net sales for the first quarter were $1,796,084 which is $465,873 or approximately 35% more than the net sales of $1,330,211 for the first quarter last year and down approximately $481,275 from the preceeding fourth quarter of last year. These changes are generally due to normal fluctuations in quarterly demands by our largest customers.

COST OF SALES
Cost of sales for the first quarter increased $109,259 or approximately 10% to $1,153,918 or 64% of sales compared to $1,044,659 or 78% of sales for the first quarter last year. This increase in cost of sales is primarily related to increased sales. Cost of sales is comprised of raw materials, manufacturing direct labor and overhead expenses. The overhead portion of cost of sales is primarily comprised of salaries, benefits, building expenses, production supplies, and maintenance costs related to our production, inventory control and quality departments.

GROSS PROFIT
Gross profit for the first quarter increased $356,614 to $642,166 or approximately 36% of sales from $285,552 or 21% of sales reported for the first quarter last year. This increase in gross profit margin reflects more efficient economies of scale at this level of sales in relation to installed capacity.

OPERATING EXPENSES
Operating expenses increased $48,016 to $310,578 from $262,562 for the same quarter last year. This increase in cost of sales is primarily related to increased sales and a payout of unused sick leave and vacation benefits. Operating expenses consist of marketing and business development expenses, professional expenses, salaries and benefits for executive and administrative personnel, hiring, legal, accounting, and other general corporate expenses.

OPERATING INCOME
The Company realized operating income of $331,588 or approximately 18% of sales for the first quarter compared to operating income of $22,990 or approximately 2% of sales, for the first quarter last year. The increase in operating income is based on the factors described above.

OTHER INCOME
Other income of $91,099 for the first quarter decreased by $67,768 from the same quarter last year. This decrease is primarily the result of the recognition of substantial capital gains from the sale of securities in the prior period.

PROVISONS FOR INCOME TAX
Income tax expense for the first quarter was $164,800 or 39% of pre-tax income compared to $69,100 or 38% of pre tax income for the first quarter last year.

NET INCOME
Net income for the first quarter that ended January 31, 2015 was $257,887 or $0.33 per share compared to $112,757 or $0.15 per share for the first quarter last year that ended January 25, 2014.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a "smaller reporting Company" as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by Item 3.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures.  As of the end of the period covered by this report, the Company conducted an evaluation, under the supervision and with the participation of the Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")). Based on this evaluation, the CEO and CFO concluded that the Company's disclosure controls and procedures are effective to reasonably ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. This information is accumulated and communicated to our management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Controls.  There were no changes in our internal controls during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, these controls over financial reporting.

10



PART II   OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are subject from time to time to certain claims and litigation in the ordinary course of business. It is the opinion of management that the outcome of such matters will not have a material adverse impact on our combined financial position or results of operations.

ITEM 1A. RISK FACTORS

Smaller reporting companies are not required to provide the information required by this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

The registrant does not have in place procedures by which stockholders may recommend nominees to the registrant's Board of Directors.

ITEM 6. EXHIBITS

  31.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  101. Financial statements from the Quarterly Report of Form 10-Q of Opt-Sciences Corporation for the period ending January 31, 2015 as interactive data files formatted in XBRL: (i) The Consolidated Balance Sheet, (ii) the Consolidated Statement of Operations, (iii) the Consolidated Statements of Cash Flows, and (iv) the Notes to the Consolidated Financial Statements.
  101.INS XBRL Instance Document.
  101.SCH XBRL Taxonomy Extension Schema Document.
  101.CAL XBRL Taxonomy Extension Calculation Linkbase Document.
  101.DEF XBRL Taxonomy Extension Definition Linkbase Document.
  101.LAB XBRL Taxonomy Extension Label Linkbase Document.
  101.PRE XBRL Taxonomy Extension Presentation Linkbase Document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Opt-Sciences Corporation
 
/s/ Anderson L. McCabe      
Anderson L. McCabe
Chief Executive Officer &
Chief Financial Officer
March 12, 2015

11